Latest @ CSI.

View All
November 18, 2024
The Frontiers in Cancer Science (FCS) 2024 , Save the Date for FCS2025
The Frontiers in Cancer Science (FCS) 2024 conference took place from November 13-15, 2024, at The Matrix, Biopolis, Singapore. We trust that all delegates had an exceptional time exchanging ideas...
Read More »
October 24, 2024
CSI Singapore Recognised in World’s Top 2% Most-Cited Scientists in 2024
CSI Singapore has been recognised in 'World’s Top 2% Most-Cited Scientists in 2024' in the latest update by Elsevier. Congratulations to Prof. Ashok and Dr. Tony for their commendable efforts...
Read More »

Press Release

View All
DDX6 induces immunosuppression in cancer by disrupting structural stability of endogenous double-stranded RNAs

Cancer cells can avoid detection by suppressing the warning signals that would alert the immune system.Led by Associate Professor Polly Chen, the team found that a protein called DDX6 helps […]

qChIP-MS reveals the local chromatin composition by label-free quantitative proteomics

Researchers led by Principal Investigator, Assistant Professor Dennis Kappei, have developed a new method that allows scientists to better understand how DNA activity is organised and regulated inside our cells. […]

An Analytic Framework Characterizes the Biological Processes That Shape Copy Number–Based Genome Instability Patterns in Breast Cancer

 A study led by Principal Investigator, Dr. Jason Pitt, has identified eight new “signatures” of DNA patterns (gains and/or losses) in breast cancer. By analysing nearly 2,800 genomes, the team […]

A Paired Sequence Language Model for Protein-Protein Interaction Modeling

Researchers led by Senior Principal Investigator, Professor Zhang Yang, have developed a new artificial intelligence (AI) model that can more accurately predict how proteins interact with one another—an advance that […]

Learned Conformational Space and Pharmacophore into Molecular Foundational Model

A key challenge in AI-driven drug discovery is moving beyond molecular analysis to enable chemically meaningful molecular design. In a newly published study in Advanced Science, researchers led by Senior […]

Pembrolizumab Plus Lenvatinib in Recurrent Gynaecological Clear Cell Carcinoma (LARA): A Multicentre, Single-Arm, Phase 2 Trial (The LANCET Oncology, Feb 2026)

A multinational study led by Principal Investigator A/Prof. David Tan and collaborators from Singapore and South Korea has demonstrated encouraging results for patients with recurrent clear cell ovarian and endometrial […]

Induction of a metabolic switch from glucose to ketone metabolism programs ketogenic diet-induced therapeutic vulnerability in lung cancer (Cell Metabolism Nov 2025)

Authors Zhengwei Wu , Zhenxun Wang , Seow Qi Ng , Jessica Alice Lidster , Paul Schwerd-Kleine , Zi Jin Cheryl Phua , Kai Lay Esther Peh , Yin Ying […]

Pragmatic Interventions to Boost Surveillance Mammogram Uptake Among an Overdue Population A Randomized Clinical Trial (JAMA Internal Medicine, Nov 2025)

Authors Soo-Chin Lee, Sasidharan Swarnalatha Lucky, Junxian Zhu, Samuel Ow, Lukas Loh, Jun Hui Tan, Siew Eng Lim, Zarinah Hairom, Shivan Mehta 6, Bee-Choo Tai, Boon-Cher Goh Abstract Led by […]

Aggressive B cell lymphomas retain ATR-dependent determinants of T cell exclusion from the germinal center dark zone (JCI, July 2025)

Authors: Valeria Cancila, Giorgio Bertolazzi, Allison S.Y. Chan, Giovanni Medico, Giulia Bastianello, Gaia Morello, Daniel Paysan, Clemence Lai, Liang Hong, Girija Shenoy, Patrick W. Jaynes, Giovanna Schiavoni, Fabrizio Mattei, Silvia […]

Prospective Clinical Validation of a Combinatorial Functional Precision Medicine Platform in Relapsed/Refractory Non-Hodgkin’s Lymphoma (JCO Precision Oncology, September 2025)

Treating patients whose non-Hodgkin’s lymphoma (NHL) has come back or stopped responding to therapy remains very difficult. Many eventually run out of standard treatment options. A team led by Dr. […]

Upcoming Events

View All
×

CSI Web Experience Survey Form